
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Currently, high-production rates and continuous production processes favor existing tableting technologies. However, if tablet development becomes rate-limiting in the future, alternative technologies may prove attractive.
over 22 years ago
Ion Exchange Resins Unique Solutions to Formulation Problemsover 22 years ago
New Developments in Spray-Dried Lactoseover 22 years ago
The Use of Acrylic Resins for Improved Aqueous Enteric Coating





